206 related articles for article (PubMed ID: 35099634)
1. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
2. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
3. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
[TBL] [Abstract][Full Text] [Related]
4. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
[TBL] [Abstract][Full Text] [Related]
6. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
7. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features of low-grade oncocytic renal tumor (CD117-negative, cytokeratin 7-positive): report of seven cases].
Xie B; Cheng LC; Yin GL; Liu BA; Hu ZL; Tong K
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):719-725. PubMed ID: 35922161
[No Abstract] [Full Text] [Related]
9. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?
Trpkov K; Williamson SR; Gao Y; Martinek P; Cheng L; Sangoi AR; Yilmaz A; Wang C; San Miguel Fraile P; Perez Montiel DM; Bulimbasić S; Rogala J; Hes O
Histopathology; 2019 Aug; 75(2):174-184. PubMed ID: 30895640
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
11. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
[TBL] [Abstract][Full Text] [Related]
12. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
13. Low grade oncocytic renal tumor (LOT): Clinicopathological characterization of 13 cases.
Almutairi F; Xu B
Pathol Res Pract; 2024 Feb; 254():155127. PubMed ID: 38241777
[TBL] [Abstract][Full Text] [Related]
14. [Eosinophilic vacuolated tumor of the kidney: clinicopathological and molecular characteristics].
Zhang HZ; Xia QY; Yin XG; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):437-443. PubMed ID: 35511640
[No Abstract] [Full Text] [Related]
15. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract][Full Text] [Related]
16. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
[TBL] [Abstract][Full Text] [Related]
17. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
Henske EP; Cornejo KM; Wu CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
[TBL] [Abstract][Full Text] [Related]
18. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
[TBL] [Abstract][Full Text] [Related]
19. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
Mansoor M; Siadat F; Trpkov K
Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
[TBL] [Abstract][Full Text] [Related]
20. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity.
Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
